scPharmaceuticals expects preliminary unaudited fourth quarter FUROSCIX net revenue to be in the range of $12 million to $12.3 million, representing a 22% increase from the third quarter of 2024 at ...

Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue. Management to Host ...

New Directors Bring Extensive Leadership Experience in Corporate Strategy and Commercialization. SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve ...

Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the inclusion of circulating tumor DNA (ctDNA) testing in the National ...

TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced that the Company is supporting partners and ...

LAVA-1266 is a potent bi-specific, T cell engager (bsTCE) that targets CD123+ tumor cells with Vγ9Vδ2-T cells using LAVA’s Gammabody ® platform. The bsTCE was designed to lyse CD123+ tumor cells with ...

Aaron Green, Chief Executive Officer, stated, “We are pleased to have now achieved compliance with both the Nasdaq minimum bid price rule and Nasdaq’s periodic financial reporting rule.” As the ...

Biosphere’s proprietary UV sterilization approach paves the way for a new generation of bioreactors that are simpler, more ...

Cannabix provides updated images of its Breath Collection Unit (“BCU”) and Breath Cartridge technology with several new ...

Immuno-oncological therapies have transformed the cancer treatment landscape. They are however only effective in a subset of patients, requiring the identification of novel immunotherapy targets. The ...

Frontier’s pipeline of precision medicines continues to progress rapidly, with interim clinical data for FMC-376, an ON+OFF KRASG12C inhibitor currently in the Phase 1/2 PROSPER trial, expected 2H ...

To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.